Welcome to our dedicated page for Mesa Laboratories news (Ticker: MLAB), a resource for investors and traders seeking the latest updates and insights on Mesa Laboratories stock.
Mesa Laboratories, Inc. (NASDAQ: MLAB) is described in its public communications as a global leader in the design and manufacture of life science tools and critical quality control solutions. Its news flow reflects this focus, with regular updates related to regulated applications in the pharmaceutical, healthcare, and medical device industries.
Visitors to this MLAB news page can review company-issued press releases covering financial results, divisional performance, and capital structure decisions. Mesa frequently announces quarterly results for its four divisions—Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics—highlighting revenues, organic and core organic revenues growth, and commentary on factors such as tariffs, foreign exchange, and geographic trends.
The news stream also includes dividend declarations, where the Board of Directors approves a regular quarterly dividend on Mesa’s common stock, along with record and payment dates. In addition, Mesa issues releases about investor conference participation and healthcare conference presentations, providing context for how management communicates with the investment community.
Another recurring theme in Mesa’s news is financing and balance sheet activity, such as the execution of strategic financing plans, use of its credit facility, and repayment or settlement of convertible notes. These items offer insight into how the company manages its capital structure alongside its operating performance.
By following this page, readers can access a chronological view of Mesa’s official announcements, including earnings releases, dividend decisions, conference appearances, and financing updates, all drawn from the company’s own disclosures.
Mesa Laboratories (NASDAQ:MLAB) reported 3Q26 results for the quarter ended December 31, 2025. Revenues were $65.126 million, up 3.6% year-over-year (7.2% sequential). AOI excluding unusual items rose to $17.072 million (26.2% of revenues). The company repaid $8.7 million of debt, lowering Total Net Leverage Ratio to 2.62.
Division results: SDC +6.0% organic, BPD +17.5% organic, CS -2.5% organic, CG -7.1% organic (China down ~57%, ~$1.2M).
Mesa Laboratories (NASDAQ:MLAB) declared a regular quarterly dividend of $0.16 per share. The dividend is payable on March 16, 2026 to shareholders of record at the close of business on February 28, 2026. The announcement reaffirms the company’s ongoing dividend program while reiterating standard forward-looking statement caution about risks and uncertainties that could affect future results.
Mesa Labs (NASDAQ:MLAB) announced that Gary Owens, President and CEO, and John Sakys, CFO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026.
The company will deliver a Formal Presentation at 4:30 p.m. Pacific Time. A live webcast will be accessible via the Events & Presentations section of Mesa Labs' Investor Relations website at https://investors.mesalabs.com/, and an archived replay will be available at the same link after the presentation.
Mesa Laboratories (NASDAQ:MLAB) will release third quarter fiscal 2026 financial results on Tuesday, February 3, 2026 at approximately 8:00 A.M. Eastern Time. The company will issue a press release with the results on that date.
Mesa Laboratories (NASDAQ:MLAB) announced senior management will attend three investor conferences in November–December 2025. Gary Owens, president and CEO, and John Sakys, CFO, will hold 1x1 meetings at the Raymond James Napa Valley Small Cap Symposium on November 17, 2025, participate in a fireside chat at the Jefferies London Healthcare Conference on November 20, 2025 at 12:00 p.m. GMT, and appear at the 8th Annual Evercore Healthcare Conference fireside chat on December 3, 2025 at 2:10 p.m. ET.
The Jefferies fireside chat will be available via live webcast, with a replay posted in the Events & Presentations section of Mesa Lab's Investor Relations website.
Mesa Laboratories (NASDAQ:MLAB) reported 2Q26 results for the quarter ended September 30, 2025. Total revenues $60,737 (up 5.0% year-over-year) and core organic revenues +3.7%. Operating income rose 34.7% to $4,724. Non-GAAP adjusted operating income (AOI) was $14,385 (+7.2%); excluding unusual items AOI was $15,233 (+6.1%) and AOI margin was 25.1%. Net income was $2,476 (down 27.8%). Total Net Leverage Ratio was 3.02. Company cited $3.2M annualized cost reductions (net annualized savings expected $2.3M) and plans to reinvest $0.9M into SDC starting 3Q25. Division highlights: BPD core organic +16.4%, CS +10.8%, CG core organic -3.6% with China down ~58% (~$1.7M), SDC core organic -3.2%.
Mesa Laboratories (NASDAQ:MLAB) announced it will release financial results for the second quarter of fiscal 2026 after market close on Thursday, November 6, 2025.
The company is a global designer and manufacturer of life science tools and quality control solutions for pharmaceutical, healthcare and medical device industries. Media and investors may contact Gary Owens, President and CEO, or John Sakys, CFO at +1-303-987-8000. More information is available at www.mesalabs.com.
Mesa Laboratories (NASDAQ:MLAB) announced on Oct 3, 2025 that its Board declared a regular quarterly dividend of $0.16 per share. The dividend is payable on Dec 15, 2025 to shareholders of record at the close of business on Nov 28, 2025.
The release includes a standard forward-looking statements caution and directs investors to the company’s Form 10-K for risks and additional information.
Mesa Laboratories (NASDAQ: MLAB) has executed its strategic financing plan by repaying $97.5 million of its 1.375% Convertible Senior Notes due August 2025. The company drew $97.0 million from its Credit Agreement, bringing the total outstanding balance to $108 million.
The Credit Facility's current interest rate is 7.18%, with potential decreases tied to Federal Funds Rate reductions and an additional 25 basis point reduction when Mesa's net leverage ratio falls below 3.0x, expected by Q3 FY2026. The company's total net leverage ratio stood at 3.16 as of June 30, 2025. Mesa plans to make approximately $20.0 million in principal payments for Q2-Q4 of fiscal year 2026, with higher payments expected in FY2027.
Mesa Laboratories (NASDAQ:MLAB) reported Q1 FY26 results with revenues increasing 2.4% to $59.5M. The company's core organic revenue growth was 0.4%, while operating income decreased 45.1% to $3.1M. Key divisional performance showed Sterilization and Disinfection Control (SDC) growing 7.5% to $25.4M, while Clinical Genomics faced challenges with a 69% revenue decline in China.
The company's adjusted operating income (AOI) excluding unusual items decreased 15.9% to 21.7% of revenues. Notable impacts included tariff surcharges in Biopharmaceutical Development causing $1.5M revenue shift to Q2, and significant foreign exchange headwinds. Net income increased 40% to $4.7M or $0.85 per diluted share, with a Total Net Leverage Ratio of 3.16.
[ "Total revenues increased 2.4% to $59.5M", "SDC division showed strong 7.5% core organic growth", "Net income increased 40% to $4.7M ($0.85 per share)", "Clinical Genomics growth of 7.9% excluding China", "Calibration Solutions achieved 4.8% core organic growth" ]FAQ
What is the current stock price of Mesa Laboratories (MLAB)?
What is the market cap of Mesa Laboratories (MLAB)?
